Skip to main content

Spotlight on Memantine in Moderate to Severe Alzheimer’s Diseasey

Drugs & Aging volume 27, pages 177–179 (2010)Cite this article

Abstract

Memantine (Axura®, Ebixa®, Namenda®) is an uncompetitive, moderate-affinity NMDA receptor antagonist that is indicated for the treatment of moderate to severe Alzheimer’s disease. In well designed trials in patients with moderate to severe Alzheimer’s disease, oral memantine monotherapy improved outcomes in the area of functional ability more than placebo in one trial, but in a second trial, treatment differences did not reach significance. Memantine has a distinct mode of action compared with that of acetylcholinesterase (AChE) inhibitors, and in a well designed study, combination therapy with memantine plus donepezil improved outcomes more than donepezil plus placebo in all four domains (function, cognition, behaviour and global change).

Memantine is generally well tolerated, with adverse events occurring with a similar incidence to that reported with placebo. In modelled cost-effectiveness analyses, memantine was dominant to no therapy in regard to cost per quality-adjusted life-year (QALY) gained, and the combination of memantine plus donepezil was dominant to donepezil therapy alone in regard to QALYs gained when treatment periods exceeded 1 year in patients with moderate to severe disease. Thus, in the management of patients with moderate to severe Alzheimer’s disease, memantine provides an effective treatment option. To date, clinical trial support is greater for memantine use in combination with an AChE inhibitor, while more data are needed to confirm its efficacy as monotherapy.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. McKeage K. Memantine: a review of its use in moderate to severe Alzheimer’s disease. CNS Drugs 2009; 23(10): 881–97

    PubMed  Article  CAS  Google Scholar 

  2. Rammes G, Danysz W, Parsons CG. Pharmacodynamics of memantine: an update. Curr Neuropharmacol 2008; 6(1): 55–78

    PubMed  Article  CAS  Google Scholar 

  3. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology 1999 Jun; 38(6): 735–67

    PubMed  Article  CAS  Google Scholar 

  4. Danysz W, Parsons CG, Mö;bius HJ, et al. Neuroprotective and symptomatological action of memantine relevant for Alzheimer’s disease: a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res 2000; 2(2–3): 85–97

    PubMed  Article  CAS  Google Scholar 

  5. Gilling KE, Jatzke C, Parsons CG. Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-D-aspartate receptors by memantine. Neuropharmacology 2007; 53(3): 415–20

    PubMed  Article  CAS  Google Scholar 

  6. Volbracht C, van Beek J, Zhu C, et al. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Eur J Neurosci 2006 May; 23(10): 2611–22

    PubMed  Article  Google Scholar 

  7. Forest Pharmaceuticals Inc. Namenda (memantine HCL) tablets/oral solution: full prescribing information [online]. Available from URL: http://www.frx.com/pi/namenda_pi.pdf [Accessed 2009 Jun 12]

  8. European Medicines Agency. Axura film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.emea.eu/humandocs/PDFs/EPAR/axura/H-378-PI-en.pdf [Accessed 2009 Jun 12]

  9. Reisberg B, Doody R, Stö;ffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003 Apr 3; 348(14): 1333–41

    PubMed  Article  CAS  Google Scholar 

  10. Reisberg B, Doody R, Stoffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006 Jan; 63(1): 49–54

    PubMed  Article  Google Scholar 

  11. van Dyck CH, Tariot PN, Meyers B, et al. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007 Apr; 21(2): 136–43

    PubMed  Article  Google Scholar 

  12. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004 Jan 21; 291(3): 317–24

    PubMed  Article  CAS  Google Scholar 

  13. Atri A, Shaughnessy LW, Locascio JJ, et al. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008; 22(3): 209–21

    PubMed  Article  CAS  Google Scholar 

  14. Doody RS, Tariot PN, Pfeiffer E, et al. Meta-analysis of six-month memantine trials in Alzheimer’s disease. Alzheimers Dement 2007; 3(1): 7–17

    PubMed  Article  CAS  Google Scholar 

  15. McShane R, Sastre AA, Minakaran N. Memantine for moderate and severe Alzheimer’s disease: systematic review and meta-analysis of 9 trials [abstract no. 02-04-04]. 12th International Conference on Alzheimer’s Disease and Related Disorders; 2008 Jul 26–31; Chicago (IL)

  16. Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007; 24(1): 20–7

    PubMed  Article  CAS  Google Scholar 

  17. Antonanzas F, Rive B, Badenas JM, et al. Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain. Eur J Health Econ 2006 Jun; 7(2): 137–44

    PubMed  Article  Google Scholar 

  18. Gagnon M, Rive B, Hux M, et al. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry 2007 Aug; 52(8): 519–26

    PubMed  Google Scholar 

  19. Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer’s disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 2004; 21(9): 607–20

    PubMed  Article  CAS  Google Scholar 

  20. Jö;nsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer’s disease in Sweden. Am J Geriatr Pharmacother 2005 Jun; 3(2): 77–86

    Article  Google Scholar 

  21. Weycker D, Taneja C, Edelsberg J, et al. Cost-effectiveness of memantine in moderate-to-severe Alzheimer’s disease patients receiving donepezil. Curr Med Res Opin 2007 May; 23(5): 1187–97

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Kate McKeage

Authors
  1. Kate McKeage
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kate McKeage.

Additional information

Adapted and reproduced from CNS Drugs 2009; 23 (10): 881–97.[1] The full text article was reviewed by: D. Adamis, Research and Academic Institute of Athens, Athens, Greece; A. Atri, Department of Neurology and Massachusetts Alzheimer’s Disease Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA; S. Gauthier, McGill Center for Studies in Aging, Douglas Hospital, Verdun, Quebec, Canada; H. Kavirajan, Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, California, USA; M.C. Woodward, Aged and Residential Care Services, Heidelberg Repatriation Hospital, Heidelberg, Victoria, Australia. The manufacturer of the agent under review was offered an opportunity to comment on the original article during the peer review process; changes based on any comments received were made on the basis of scientific and editorial merit. The preparation of the original article and this spotlight was not supported by any external funding.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

McKeage, K. Spotlight on Memantine in Moderate to Severe Alzheimer’s Diseasey. Drugs Aging 27, 177–179 (2010). https://doi.org/10.2165/11204670-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11204670-000000000-00000

Keywords

  • Memantine
  • Galantamine
  • AChE Inhibitor
  • Recommend Maintenance Dosage
  • Clinical Trial Support